Therefore, the identification of physiopathological HLA-E peptide ligands and development of single high affinity receptors such that have been shown for chimeric antigen receptors on T cells against acute lymphoid leukemia [52] is one obstacle that needs to be overcome for future therapy concepts. This evidence concerns the gene HLA-E and acute lymphoblastic leukemia.